"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
The development of thrombosis has been reported after doses exceeding 20 units/kg body weight of Berinert when used off-label1 in newborns and young children with congenital heart anomalies during or after cardiac surgery under extracorporeal circulation. The maximum dose administered in clinical studies in hereditary angioedema was 20 units/ kg body weight. Overdosage did not occur in connection with treatment of HAE.
Berinert is contraindicated in individuals who have experienced life-threatening hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor preparations.
Last reviewed on RxList: 9/15/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Berinert Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.